[Transfer factor (TF) treatment of patients with HBs-Ag-positive chronic active hepatitis. A prospective, controlled study (author's transl)]. 1979

C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini

It is a clinically and experimentally well supported working hypothesis that infection with hepatitis B virus may result in chronic active hepatitis in patients with suspected immune deficiencies. On this basis, a pilot study was performed in order to evaluate the effect of "specific" transfer factor (TF) in the treatment of HBS-Ag-positive chronic active hepatitis. From the leukocytes of 500 ml venous blood each of 40 volunteers that had completely recovered from acute virus hepatitis B within the last 6 months, a unique TF pool (40 units of TF) was prepared according to the method of Lawrence. Preexaminations indicated that this preparation was able to enhance cellular immune reactions in vitro. Thirteen patients with HBS-antigenemia and chronic active hepatitis (i.e., two liver biopsies within the last 6 or more months with the histological criteria of chronic aggressive hepatitis according to de Groote, elevated serum levels of bilirubin, alkaline phosphatase, transaminase activities, and/or gamma-globulines) were randomized: Seven received s.c. injections of two units of TF each on days 1 and 15, the other six saline. Conversion of skin reactions to some ubiquitous antigens occurred in the TF group, but no significant and constant drop of HBS-Ag serum titers was observed. Although some of the biochemical parameters seemed to ameliorate in the TF group, the differences versus the control group did not prove to be significant within the limited number of patients under observation. The in vitro reactivity of patients' lymphocytes to HBS-Ag, tested by means of the 3H-thymidine uptake, was never found enhanced after TF application. In the used doses, "specific" TF was not effective in the treatment of HBS-Ag-positive chronic active hepatitis; unfavorable side-effects were not observed.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
May 1978, Deutsche medizinische Wochenschrift (1946),
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
December 1978, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
August 1981, Tissue antigens,
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
March 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
August 1980, Deutsche medizinische Wochenschrift (1946),
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
July 1977, Tissue antigens,
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
June 1980, Lijecnicki vjesnik,
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
March 1981, Pathologie-biologie,
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
January 1976, Bollettino dell'Istituto sieroterapico milanese,
C P Sodomann, and G Maerker-Alzer, and K Havemann, and C Dienst, and H Schultz, and D Mitrenga, and K Schumacher, and G A Martini
May 1981, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Copied contents to your clipboard!